Pharmaceuticals

The Drug Repurposing Market Is Witnessing Impact From Rising Prevalence Of Cardiovascular Diseases Driving Growth In The

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Drug Repurposing Market Progress Between 2026 And 2030?

The drug repurposing market has experienced substantial growth in recent years. It is projected to expand from $37.38 billion in 2025 to $40.95 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. The historical expansion of this market can be attributed to several factors, including the significant cost and time involved in traditional drug discovery, a rising number of failed drug candidates, the increasing prevalence of chronic and rare diseases, limited therapeutic options for emerging diseases, and the early adoption of computational methods for drug repositioning.

The drug repurposing market is anticipated to experience robust expansion over the coming years, projected to reach $58.33 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This growth throughout the forecast period stems from factors such as the integration of AI and machine learning in drug repurposing, increasing investment in biotech and pharmaceutical research, the broadening capabilities of contract research organizations (CROs), a heightened demand for cost-effective therapies, and supportive regulatory frameworks for repurposed drug approvals. Key trends expected during this period involve a greater emphasis on phenotypic and target-based screening, the growing acceptance of structure-based drug repositioning, the development of off-target activity identification methods, the wider application of drug repurposing for rare and infectious diseases, and the reduction of drug development timelines by leveraging existing molecules.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

Which Drivers Are Supporting The Drug Repurposing Market Growth?

The expanding occurrence of neurodegenerative conditions is anticipated to fuel the expansion of the drug repurposing market in the future. These diseases are a category of ailments marked by the gradual deterioration of neuron structure or function, ultimately leading to their demise. The surge in neurodegenerative conditions, for instance, Alzheimer’s dementia, stems from longer life expectancies, given that aging serves as the main risk factor for the progressive decline of neuronal activity over time. Drug repurposing aids in addressing neurodegenerative diseases by pinpointing established medications with verified safety records that can be re-purposed to target specific disease mechanisms, thereby expediting the creation of efficacious therapies. As an illustration, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts predicting a rise to 13.8 million by 2060. Consequently, the increasing occurrence of neurodegenerative disorders is propelling the expansion of the drug repurposing market.

How Are Segments Identified Within The Drug Repurposing Market Segment Framework?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Which Trends Are Contributing To Changes In The Drug Repurposing Market?

Key players within the drug repurposing sector are prioritizing the creation of sophisticated tools, including artificial intelligence (AI)-driven drug-protein interaction modeling, to hasten the discovery of novel therapeutic applications for existing medications. This AI-enabled drug-protein interaction modeling utilizes AI and machine learning capabilities to forecast drug interactions with proteins throughout the human proteome, employing vast datasets to boost both precision and reliability. For example, in July 2025, Cosmos Health Inc., a US-based healthcare firm, launched Cloudscreen 2.0, an advanced AI platform specifically for drug repurposing initiatives. The system represents a next-generation design, capable of processing datasets more than 100 times larger than previous versions, which allows for thorough analysis of drug-protein interactions. Incorporating mutagenesis data and specific tools for assessing disordered proteins, this platform is geared towards addressing diseases like cancer, obesity, and diabetes. Moreover, its foundation in graphics processing unit (GPU)-based cloud computing facilitates scalable processing, establishing the platform as a pivotal innovation for accelerating research and development pipelines in drug repurposing across numerous therapeutic fields.

Who Are The Companies Competing Within The Drug Repurposing Market?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Get The Full Drug Repurposing Market Report:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

Which Geographic Region Dominates The Drug Repurposing Market?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Repurposing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

Browse Through More Reports Similar to the Global Drug Repurposing Market 2026, By The Business Research Company

Pharmacy Repackaging Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795